Morepen Laboratories also defaulted in payment of interest and principal of compulsory redeemable preference shares worth Rs 33.4 crore to banks.
Consolidated total revenue of the company also rose to Rs 219.74 crore for the quarter under consideration as against Rs 171.75 crore for the same period a year ago.
Keynotes Financial Opiniery is bullish on Morepen Laboratories has recommended buy rating on the stock with a target price of Rs 24 in its research report dated March 22, 2019.
The two active pharmaceutical ingredients (APIs) collectively constitute 44 per cent of the company's total API business, Morepen Laboratories said.
Ashwani Gujral of ashwanigujral.com recommends buying Jubilant Life Sciences, Mindtree and IDFC Bank.
"The US Food and Drug Administration (USFDA) has cleared Montelukast Sodium, a bulk drug/API manufactured by Morepen Laboratories, for sale in the US market," the company said in a regulatory filing.
The company had posted a net profit of Rs 2.76 crore for the corresponding period of the previous fiscal, it said in a statement.
Morepen Laboratories Ltd. has reported a 118 per cent rise in its net profit (profit after tax) for the Second quarter (Q2) of FY ...
Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have - Bharat Financial Inclusion, SRF, DLF, Morepen Laboratories, Adlabs Entertainment, Dishman Pharmaceuticals and Chemicals & Sintex Industries.
Morepen Laboratories shares rallied as much as 10 percent Friday after a media report indicated that Piramal Enterprises is in talks to buy company's OTC business.
L&T Technology Services | L&T | DLF | BHEL | Majesco | Adani Enterprises | Sun Pharma | Bharat Financial Inclusion | BPCL | Morepen Labs | Websol Energy | Den Networks | NHPC and Indian Hotels are stocks, which are in the news today.
Sharmila Joshi of sharmilajoshi.com is of the view that one may book some profits in Morepen Laboratories.
The company expects to notch a global turnover of Rs 100 crore from this bulk drug alone in 2016-17.
Vishal Malkan of malkansview.com advises selling CESC with a target of Rs 540.
Morepen Laboratories has reported a standalone sales turnover of Rs 90.28 crore and a net loss of Rs 2.02 crore for the quarter ended Dec '13
Morepen Laboratories has reported a standalone sales turnover of Rs 79.01 crore and a net loss of Rs 1.28 crore for the quarter ended Sep '13
Morepen Laboratories has reported a sales standalone turnover of Rs 79.74 crore and a net profit of Rs 0.57 crore for the quarter ended Jun '13
Morepen Laboratories has reported a standalone sales turnover of Rs 81.01 crore and a net loss of Rs 3.98 crore for the quarter ended Mar '13